DDInter93 DDInter624
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Anagrelide {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is regulated by {v} (Gene) TBX2
TBX2 {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) regulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) downregulates {v} (Gene) EBP
EBP {u} (Gene) is upregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) upregulates {v} (Gene) PCBD1
PCBD1 {u} (Gene) is upregulated by {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Anagrelide {u} (Compound) upregulates {v} (Gene) PCBD1
PCBD1 {u} (Gene) regulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Efavirenz (Compound)
Anagrelide (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Anagrelide (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Anagrelide (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is regulated by TBX2 (Gene) and TBX2 (Gene) is upregulated by Efavirenz (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Anagrelide (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) regulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Anagrelide (Compound) downregulates EBP (Gene) and EBP (Gene) is upregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Anagrelide (Compound) upregulates PCBD1 (Gene) and PCBD1 (Gene) is upregulated by acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Anagrelide (Compound) upregulates PCBD1 (Gene) and PCBD1 (Gene) regulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)